Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2

(2009) J. Copp et al.   CANCER RESEARCH

In This Issue

(2009)   CELL

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

(2009) Sherif S. Farag et al.   LEUKEMIA RESEARCH

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin

(2009) P. Frost et al.   MOLECULAR CANCER THERAPEUTICS

mTORC2 is the hydrophobic motif kinase for SGK1

(2008) Lijun Yan et al.   BIOCHEMICAL JOURNAL

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors

(2008) S. Sharma et al.   BLOOD

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma

(2008) A. Zollinger et al.   BLOOD

Involvement of Hepcidin in the Anemia of Multiple Myeloma

(2008) S. Sharma et al.   CLINICAL CANCER RESEARCH

Wnt Signaling Inhibits Forkhead Box O3a-induced Transcription and Apoptosis through Up-regulation of Serum- and Glucocorticoid-inducible Kinase 1

(2008) Manuel Dehner et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA